You just read:

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira®

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jul 27, 2017, 09:56 ET